44 related articles for article (PubMed ID: 31273933)
1. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
Tacconi EM; Badie S; De Gregoriis G; Reisländer T; Lai X; Porru M; Folio C; Moore J; Kopp A; Baguña Torres J; Sneddon D; Green M; Dedic S; Lee JW; Batra AS; Rueda OM; Bruna A; Leonetti C; Caldas C; Cornelissen B; Brino L; Ryan A; Biroccio A; Tarsounas M
EMBO Mol Med; 2019 Jul; 11(7):e9982. PubMed ID: 31273933
[TBL] [Abstract][Full Text] [Related]
2. FANCD2 limits replication stress and genome instability in cells lacking BRCA2.
Michl J; Zimmer J; Buffa FM; McDermott U; Tarsounas M
Nat Struct Mol Biol; 2016 Aug; 23(8):755-757. PubMed ID: 27322732
[TBL] [Abstract][Full Text] [Related]
3. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.
Reisländer T; Lombardi EP; Groelly FJ; Miar A; Porru M; Di Vito S; Wright B; Lockstone H; Biroccio A; Harris A; Londoño-Vallejo A; Tarsounas M
Nat Commun; 2019 Jul; 10(1):3143. PubMed ID: 31316060
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant stratification of lung squamous carcinoma patients based on ubiquitinated proteasome genes for 3P medical approach.
Yang J; Ouedraogo SY; Wang J; Li Z; Feng X; Ye Z; Zheng S; Li N; Zhan X
EPMA J; 2024 Mar; 15(1):67-97. PubMed ID: 38463626
[TBL] [Abstract][Full Text] [Related]
5. RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles.
Longo MA; Roy S; Chen Y; Tomaszowski KH; Arvai AS; Pepper JT; Boisvert RA; Kunnimalaiyaan S; Keshvani C; Schild D; Bacolla A; Williams GJ; Tainer JA; Schlacher K
Nat Commun; 2023 Jul; 14(1):4445. PubMed ID: 37488098
[TBL] [Abstract][Full Text] [Related]
6. Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities.
Rudd SG
Cancer Chemother Pharmacol; 2023 Oct; 92(4):241-251. PubMed ID: 37452860
[TBL] [Abstract][Full Text] [Related]
7. Two-Step Validation Approach for Tools To Study the DNA Repair Enzyme SNM1A.
Fay EM; Newton A; Berney M; El-Sagheer AH; Brown T; McGouran JF
Chembiochem; 2023 Jul; 24(13):e202200756. PubMed ID: 36917742
[TBL] [Abstract][Full Text] [Related]
8. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230543
[TBL] [Abstract][Full Text] [Related]
9. Homologous Recombination Deficiency Scar: Mutations and Beyond-Implications for Precision Oncology.
van der Wiel AMA; Schuitmaker L; Cong Y; Theys J; Van Hoeck A; Vens C; Lambin P; Yaromina A; Dubois LJ
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077694
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of a Prognostic Classifier Based on Lipid Metabolism-Related Genes for Breast Cancer.
Wang N; Gu Y; Li L; Chi J; Liu X; Xiong Y; Zhong C
J Inflamm Res; 2022; 15():3477-3499. PubMed ID: 35726216
[TBL] [Abstract][Full Text] [Related]
11.
Devico Marciano N; Kroening G; Dayyani F; Zell JA; Lee FC; Cho M; Valerin JG
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626055
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours.
Groelly FJ; Porru M; Zimmer J; Benainous H; De Visser Y; Kosova AA; Di Vito S; Serra V; Ryan A; Leonetti C; Bruna A; Biroccio A; Tarsounas M
EMBO Mol Med; 2022 Mar; 14(3):e14501. PubMed ID: 35107878
[TBL] [Abstract][Full Text] [Related]
13. KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Liu X; Qiu R; Xu M; Meng M; Zhao S; Ji J; Yang Y
Breast Cancer Res Treat; 2021 Sep; 189(2):347-361. PubMed ID: 34240274
[TBL] [Abstract][Full Text] [Related]
14. Identification of Bioactive SNM1A Inhibitors.
Buzon B; Grainger RA; Rzadki C; Huang SYM; Junop M
ACS Omega; 2021 Apr; 6(14):9352-9361. PubMed ID: 33869915
[TBL] [Abstract][Full Text] [Related]
15. Appended Aromatic Moieties in Flexible Bis-3-chloropiperidines Confer Tropism against Pancreatic Cancer Cells.
Carraro C; Helbing T; Francke A; Zuravka I; Sosic A; De Franco M; Gandin V; Gatto B; Göttlich DR
ChemMedChem; 2021 Mar; 16(5):860-868. PubMed ID: 33200541
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
Rieckhoff J; Meyer F; Classen S; Zielinski A; Riepen B; Wikman H; Petersen C; Rothkamm K; Borgmann K; Parplys AC
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003585
[TBL] [Abstract][Full Text] [Related]
17. Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C.
Chen X; Peng F; Ji Y; Xiang H; Wang X; Liu T; Wang H; Han Y; Wang C; Zhang Y; Kong X; Lang JY
Cell Death Dis; 2020 Sep; 11(9):812. PubMed ID: 32980867
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
19. Effect of sodium butyrate on ABC transporters in lung cancer A549 and colorectal cancer HCT116 cells.
Shi B; Xu FF; Xiang CP; Jia R; Yan CH; Ma SQ; Wang N; Wang AJ; Fan P
Oncol Lett; 2020 Nov; 20(5):148. PubMed ID: 32934716
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
